Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tai United Holdings Limited (0718.HK)
North Point, HK
Tai United Holdings Limited operates as an investment holding company, primarily directing its capital into real estate ventures across the People's Republic of China, Singapore, the United States, the United Kingdom, and the Republic of Mongolia. The firm's operations are structured into five principal divisions: Property Investment, Medical Equipment Trading, Flooring Materials Trading, Mining and Exploitation of Natural Resources, and Financial Services and Asset Management. The Property Investment segment is responsible for acquiring, managing, and leasing various properties, in addition to developing retail complexes. The Medical Equipment Trading division engages in the commerce of healthcare apparatus. Flooring Materials Trading specializes in the distribution and sale of floor coverings. The Mining and Exploitation of Natural Resources segment focuses on the extraction and production of tungsten resources. Lastly, the Financial Services and Asset Management segment handles trading in equity securities and derivatives, as well as overseeing assets that originate from the acquisition of distressed debts. Established in 1995, the company was formerly recognized as Bestway International Holdings Limited before officially adopting the name Tai United Holdings Limited in August 2016. Its corporate headquarters are located in North Point, Hong Kong, and it functions as a subsidiary of Songbird SG PTE. Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +3.23% | -3.03% | -8.57% | +10.34% | +0.00% | +18.52% | -30.43% | -82.51% | -96.60% | -99.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Distribution: +5.6%+2.7% Q4'25: +118.1% (vs Q3'24)
-
EPS growth Medical - Distribution: +4.9%+49.4% ★ Q4'25: +31.8% (vs Q3'24)
-
FCF margin FCF growth · Medical - Distribution: +37.6%-166.8% Q4'25: +39.9% (vs Q3'24)
-
EBIT margin Medical - Distribution: +3.0%-65.7% Q4'25: -58.0% (vs Q3'24)
-
ROIC Medical - Distribution: +5.7%— Q4'25: +17.7% (vs Q3'24)
-
Share dilution Medical - Distribution: +0.0%+0.0% Q4'25: 0.0% (vs Q3'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×-19.15× Q4'25: -11.18× (vs Q3'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Shigong Su | Executive Chairman | 1M | male |
| Yuhua Yang | Chief Executive Officer & Executive Director | 1M | female |
| Chow Lung Lee | Executive Vice President and Head of General Marketing & Business Development | — | male |
| Yick Pang Poon FCPA | Chief Financial Officer & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0718.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
